Sansure Biotech announced that the company will invest CNY 90.93 million, accounting for 53.2% of the shares, and jointly establish Hunan Sansure Ansai Biotechnology.

After the establishment of the company, it will act as the investment body of Shenzhen Ansai through equity transfer and capital increase, etc. After the investment is completed, the joint venture company will hold 68.207% of the equity of Shenzhen Ansai.

Shenzhen Ansai is a company that develops, manufactures and sells immunodiagnostic analyzers and diagnostic reagents based on its "enhanced electrochemiluminescence" platform technology, which has its own intellectual property rights. Its founder and patent inventor of the core technology platform, Dr. Ming Zhou, has many years of experience in technology research and industrialization, and is a leading scientist and industrial transformation expert in the field of electrochemiluminescence in China. Shenzhen Ansai has synergy with the company's business, which helps the company to enter the immunoassay market with the characteristic advantages of electrochemiluminescence and accelerate the establishment of a diversified platform enterprise in the field of in vitro diagnostics.